Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

George E. Bigelow, Ph.D.

Headshot of George E. Bigelow
  • Director, Behavioral Pharmacology Research Unit
  • Professor of Psychiatry and Behavioral Sciences




Johns Hopkins Bayview Medical Center

Appointment Phone: 410-550-0035
4940 Eastern Avenue
Baltimore, MD 21224 map



  • Director, Behavioral Pharmacology Research Unit
  • Professor of Psychiatry and Behavioral Sciences

Departments / Divisions

Centers & Institutes


Additional Training

  • University of Minnesota, Minneapolis, Minnesota, 1971, Psychopharmacology

Research & Publications

Research Summary

Clinical research on substance abuse and its treatment. Human laboratory clinical pharmacology research evaluates the abuse liability and the subjective, behavioral, and physiological effects of drugs of abuse and of medications being developed or evaluated as possible treatments for substance abuse.Outpatient clinical trials research evaluates pharmacological and psychosocial treatments (especially incentive-based contingency management procedures) for substance abuse, and predictors of treatment response. Director of postdoctoral research training program in the behavioral pharmacology of substance abuse.

Selected Publications

  1. Walsh, S.L., Sullivan, J.T., Preston, K.L., Garner, J.E., & Bigelow, G.E.  (1996).  The effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. Journal of Pharmacology and Experimental Therapeutics,  279, 524-538.  
  2. Bigelow, G. E., & Walsh, S.L. (1998).  Evaluation of potential pharmacotherapies: response to cocaine challenge in the human laboratory.  In S. Higgins & J. Katz (Eds.). Cocaine Abuse Research: Pharmacology, Behavior, and Clinical Applications. (pp. 209-238 )
  3. Academic Press, CA.  Bigelow, G.E. & Silverman, K. (1999).  Theoretical and empirical foundations of contingency management treatments for drug abuse.  In S.T. Higgins and K. Silverman (Eds.), Motivating Behavior Change Among Illicit-Drug Abusers  (pp. 15-31). 
  4. Washington, DC: American Psychological Association.  Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE.  A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.  New England Journal of Medicine. 2000 2;343(18):1290-7.  
  5. Griffiths RR, Bigelow GE, Ator NA. (2003).  Principles of initial experimental drug abuse liability assessment in humans.  Drug and Alcohol Dependence, 70 (3) Supplement 1 ,.S41-S54. 

Contact for Research Inquiries

Johns Hopkins Bayview Medical Campus
Baltimore, MD 21224 map
Phone: 410-550-0035
Fax: 410-550-0030

Email me

Is this you? Edit Profile
back to top button